Ankylosing Spondylitis and Health-Related Quality of Life
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - April 17, 2019 Category: Orthopaedics Tags: CME Article Source Type: news
Why do patients turn to the internet for health information?
Lack of trust in physicians, lack of information about biologics, medicine substitutions and the search for alternative therapies are among the reasons patients turn to the internet, a new study shows. (Source: ConsultantLive)
Source: ConsultantLive - March 5, 2019 Category: Internal Medicine Authors: Whitney J. Palmer Tags: Ankylosing Spondylitis Source Type: news
VTE Risk High in Ankylosing Spondylitis (CME/CE)
(MedPage Today) -- Risk of DVT significantly elevated; less risk seen for PE (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 25, 2019 Category: Primary Care Source Type: news
VTE Risk High in Spine Disease
(MedPage Today) -- More deep venous thrombosis than pulmonary embolism seen in ankylosing spondylitis (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - February 14, 2019 Category: Rheumatology Source Type: news
Secukinumab cost-effective option in ankylosing spondylitis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news
IBD Risk Low in Patients Taking Secukinumab (CME/CE)
(MedPage Today) -- IBD events rare across 21 clinical trials for patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis given the agent (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 29, 2019 Category: Dermatology Source Type: news
IBD Rates Low in Patients on Cosentyx
(MedPage Today) -- Analysis of data from 21 clinical trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 25, 2019 Category: Dermatology Source Type: news
Patients With Spine Disease Face Lower Health-Related QOL (CME/CE)
(MedPage Today) -- Swedish study finds greater impact on physical versus mental components in ankylosing spondylitis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 7, 2019 Category: Primary Care Source Type: news
Spine Disease Hampers Quality of Life
(MedPage Today) -- But some key factors in ankylosing spondylitis may be modifiable (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 28, 2018 Category: Primary Care Source Type: news
IL-17A Response Independent of CRP in Ankylosing Spondylitis
(MedPage Today) -- Secukinumab effective even with normal levels of inflammatory marker (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 29, 2018 Category: Primary Care Source Type: news
Ixekizumab Improves Outcomes of Ankylosing Spondylitis Ixekizumab Improves Outcomes of Ankylosing Spondylitis
Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 6, 2018 Category: Orthopaedics Tags: Rheumatology News Source Type: news
Long-term Secukinumab Effective for Ankylosing Spondylitis Long-term Secukinumab Effective for Ankylosing Spondylitis
The long-term results are welcome news because about half of patients do not respond to TNF inhibitors, which are the only treatment currently available for ankylosing spondylitis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Immune therapy generates promising results in hard-to-treat ankylosing spondylitis
(Wiley) Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis (AS), a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2018 Category: International Medicine & Public Health Source Type: news
Amgen Releases AMGEVITA for Treatment of Inflammatory Diseases in Adults
The AMGEVITA is a biosimilar designed to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis hidradenitis and panuveitis. The biosimilar is a citrate-free formula and will be released in twenty-eight countries in the European Union.This story is related to the following:Biopharmaceuticals (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - October 18, 2018 Category: Medical Devices Source Type: news
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx ® leadership in spondyloarthritis
Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and MEASURE 1 studies for Cosentyx® (secukinumab) in patients with psoriatic arthritis (PsA)[1] and ankylosing spondylitis (AS)[2] respectively. (Source: World Pharma News)
Source: World Pharma News - October 16, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
